• Direct Last minute of the coronavirus in Spain

  • Holidays Keys for a safe summer for children even away from the vaccine against the virus

  • Immunization Why is the mask still necessary with 25% of the vaccinated population?

The Spanish Agency for Medicines and Health Products (AEMPS) has published this Wednesday the

6th Pharmacovigilance Report on Covid-19 Vaccines

, which includes the

notifications of adverse events

registered in Spain after immunization against Covid with the four vaccines ( Pfizer / BioNTech, Moderna, Oxford / AstraZeneca and Janssen) licensed to date.

"Until May 30, a total of 24,491 notifications of adverse events have been registered in the Fedra database (Spanish Pharmacovigilance, Adverse Reaction Data), which would correspond to

93 notifications per 100,000 doses administered

. 77% have been communicated by health professionals and 23% by citizens. Most of the notifications correspond to people between 18 and 65 years of age (88%), and mostly to women (79%) ", according to the report.

However, the AEMPS clarifies that, although these data collect reports of adverse events occurring after immunization, "adverse reactions due to the vaccine cannot be considered

until a causal relationship

with its administration

is confirmed


Only 19% of notifications were serious

In addition to this, the report reflects that, of the 24,491 notifications of adverse events registered,

4,659 were considered serious

(19%), "understood as any adverse event that requires or prolongs hospitalization, gives rise to significant or persistent disability , or to a congenital malformation, life-threatening or fatal, as well as any other condition that is considered medically significant. "

Along with this, the document indicates that it should be taken into account that the notification of serious adverse events and their registration is a priority compared to those considered not serious.

On this, among the main conclusions of this sixth report, it stands out that the

most frequently reported events

continue to be general disorders (fever and pain in the vaccination area), of the nervous system (headache and dizziness), and of the musculoskeletal system (myalgia and arthralgia).

About each vaccine

In addition to these considerations, the report provides information on each of the vaccines after

reviewing the




With regard to



, diarrhea and delayed-onset local reactions have been incorporated into the technical data sheet and package insert as possible adverse reactions. Immune thrombocytopenia cases continue to be studied, pending analysis of additional data to determine if there is any causal relationship with the administration of the vaccine.

Regarding the

Oxford / AstraZeneca



the administration of the second dose has been contraindicated in people who have suffered from thrombosis syndrome with thrombocytopenia (TTS) after the first dose, including additional information in the technical data sheet and the package leaflet about this possible. adverse reaction. In addition, the administration of this vaccine has been contraindicated in people with a history of systemic capillary leak syndrome (SFCS). "SFCS, urticaria and angioedema have been identified as new adverse reactions in the technical data sheet and the package insert. Signs related to immune thrombocytopenia and acute macular neuroretinopathy continue to be evaluated," the AEMPS details in the report.

Regarding the



, the information in the technical data sheet and the package leaflet has been updated, including recommendations for a better identification of cases of STT that may occur.

Myocarditis and pericarditis

In addition to this, the sixth pharmacovigilance report includes that the Committee for the Evaluation of Risks in Pharmacovigilance (PRAC) continues with the evaluation of the cases reported after vaccination against Covid of


(inflammation of the heart muscle) and


(inflammation of the membrane that surrounds the heart). This evaluation began after a series of cases reported in Israel became known. Most of these cases were not serious, resolved within a few days, and mostly affected young men (under 30 years of age), with symptoms beginning a few days after the vaccine was administered (almost all after receiving the second dose of the Pfizer vaccine).

"In the countries of the European Economic Area (EEA), notifications of myocarditis and / or pericarditis have also been received for the different vaccines that are being administered. At this time,

it cannot be established that there is a causal relationship

between the appearance of myocarditis or pericarditis, and vaccination. The evaluation is ongoing and will include new data that will be available soon ", added the AEMPS.

According to the criteria of The Trust Project

Know more

  • Coronavirus

  • AstraZeneca

  • Covid 19

  • Vaccines

  • Janssen vaccine

  • Pfizer vaccine

Covid-19 Vaccines begin to lose efficacy against the Delta variant, which already causes "community transmission" in Madrid

SaludSanidad will vaccinate with Pfizer the second doses of those under 60 vaccinated with AstraZeneca

SaludSanidad approved the second dose with Pfizer despite the warning of its experts that "it violates the basic principle of clinical research"

See links of interest

  • Work calendar


  • Best Universities

  • Hungary - Portugal, live

  • France - Germany, live

  • Barça - Real Madrid